UCL to harness Synpromics' promotors in gene therapy collaboration
Synpromics will make synthetic promotors for a collaboration with UCL Great Ormond Street Institute of Child Health to develop gene therapies for blood-based disorders.
Synpromics will make synthetic promotors for a collaboration with UCL Great Ormond Street Institute of Child Health to develop gene therapies for blood-based disorders.
Eli Lilly’s arthritis monoclonal antibody Taltz (ixekizumab) has been approved for a second indication in Europe.
The need for CDMOs with commercial gene therapy capacity is growing says Fujilfilm Diosynth Biotechnologies, which has opened an 80,000 square-foot plant in Texas.